Jacobio Pharmaceuticals Co., Ltd.
Clinical trials sponsored by Jacobio Pharmaceuticals Co., Ltd., explained in plain language.
-
New drug JAB-2485 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 102 people will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New hope for advanced cancers? JAB-8263 enters human testing
Disease control Recruiting nowThis study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New pill targets tough cancers: early trial hopes to shrink tumors
Disease control Recruiting nowThis study tests a new drug called JAB-23E73 in adults with advanced solid tumors that have a specific genetic change (KRAS). The main goals are to find a safe dose and see if the drug can shrink tumors. About 294 people will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 05, 2026 12:07 UTC